Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. more
Time Frame | PRTA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -3.51% | -3.39% | 0.2% |
1-Month Return | 3.92% | -1.92% | 2.72% |
3-Month Return | -36.01% | -10.54% | 7.31% |
6-Month Return | -31.08% | -4.47% | 10.44% |
1-Year Return | -61.73% | 4.06% | 27.53% |
3-Year Return | -70.12% | 0.94% | 30.88% |
5-Year Return | 9.01% | 36.67% | 89.21% |
10-Year Return | -29.66% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 814.00K | 853.00K | 200.58M | 53.91M | 91.37M | [{"date":"2019-12-31","value":0.41,"profit":true},{"date":"2020-12-31","value":0.43,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":26.87,"profit":true},{"date":"2023-12-31","value":45.55,"profit":true}] |
Cost of Revenue | 50.84M | 74.88M | 82.28M | 6.74M | 220.57M | [{"date":"2019-12-31","value":23.05,"profit":true},{"date":"2020-12-31","value":33.95,"profit":true},{"date":"2021-12-31","value":37.3,"profit":true},{"date":"2022-12-31","value":3.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (50.02M) | 853.00K | 200.58M | 53.91M | (129.20M) | [{"date":"2019-12-31","value":-24.94,"profit":false},{"date":"2020-12-31","value":0.43,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":26.87,"profit":true},{"date":"2023-12-31","value":-64.41,"profit":false}] |
Gross Margin | (6145.21%) | 100.00% | 100.00% | 100.00% | (141.40%) | [{"date":"2019-12-31","value":-6145.21,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-141.4,"profit":false}] |
Operating Expenses | 86.57M | 113.59M | 128.60M | 185.46M | 282.41M | [{"date":"2019-12-31","value":30.66,"profit":true},{"date":"2020-12-31","value":40.22,"profit":true},{"date":"2021-12-31","value":45.54,"profit":true},{"date":"2022-12-31","value":65.67,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (85.70M) | (112.73M) | 71.97M | (131.56M) | (191.04M) | [{"date":"2019-12-31","value":-119.06,"profit":false},{"date":"2020-12-31","value":-156.63,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-182.78,"profit":false},{"date":"2023-12-31","value":-265.42,"profit":false}] |
Total Non-Operating Income/Expense | 16.60M | 2.68M | (12.00K) | 12.30M | 61.57M | [{"date":"2019-12-31","value":26.96,"profit":true},{"date":"2020-12-31","value":4.35,"profit":true},{"date":"2021-12-31","value":-0.02,"profit":false},{"date":"2022-12-31","value":19.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (77.30M) | (111.43M) | 71.92M | (125.61M) | (160.48M) | [{"date":"2019-12-31","value":-107.48,"profit":false},{"date":"2020-12-31","value":-154.93,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-174.64,"profit":false},{"date":"2023-12-31","value":-223.13,"profit":false}] |
Income Taxes | 379.00K | (283.00K) | 4.95M | (8.66M) | (13.45M) | [{"date":"2019-12-31","value":7.66,"profit":true},{"date":"2020-12-31","value":-5.72,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-175.01,"profit":false},{"date":"2023-12-31","value":-271.98,"profit":false}] |
Income After Taxes | (77.68M) | (111.14M) | 66.97M | (116.95M) | (147.03M) | [{"date":"2019-12-31","value":-115.98,"profit":false},{"date":"2020-12-31","value":-165.95,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-174.62,"profit":false},{"date":"2023-12-31","value":-219.53,"profit":false}] |
Income From Continuous Operations | (77.68M) | (111.14M) | 66.97M | (116.95M) | (147.03M) | [{"date":"2019-12-31","value":-115.98,"profit":false},{"date":"2020-12-31","value":-165.95,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-174.62,"profit":false},{"date":"2023-12-31","value":-219.53,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (77.68M) | (111.14M) | 66.97M | (116.95M) | (147.03M) | [{"date":"2019-12-31","value":-115.98,"profit":false},{"date":"2020-12-31","value":-165.95,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-174.62,"profit":false},{"date":"2023-12-31","value":-219.53,"profit":false}] |
EPS (Diluted) | (1.95) | (2.79) | 1.09 | (2.51) | (2.80) | [{"date":"2019-12-31","value":-178.9,"profit":false},{"date":"2020-12-31","value":-255.96,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-230.28,"profit":false},{"date":"2023-12-31","value":-256.88,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PRTA | |
---|---|
Cash Ratio | 11.19 |
Current Ratio | 11.52 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PRTA | |
---|---|
ROA (LTM) | -15.66% |
ROE (LTM) | -22.90% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PRTA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.10 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.90 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PRTA | |
---|---|
Trailing PE | NM |
Forward PE | 64.10 |
P/S (TTM) | 5.67 |
P/B | 1.27 |
Price/FCF | NM |
EV/R | 1.28 |
EV/Ebitda | NM |
PEG | 0.80 |
Prothena Corporation plc (PRTA) share price today is $12.965
Yes, Indians can buy shares of Prothena Corporation plc (PRTA) on Vested. To buy Prothena Corporation plc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PRTA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Prothena Corporation plc (PRTA) via the Vested app. You can start investing in Prothena Corporation plc (PRTA) with a minimum investment of $1.
You can invest in shares of Prothena Corporation plc (PRTA) via Vested in three simple steps:
The 52-week high price of Prothena Corporation plc (PRTA) is $41.55. The 52-week low price of Prothena Corporation plc (PRTA) is $12.31.
The price-to-earnings (P/E) ratio of Prothena Corporation plc (PRTA) is
The price-to-book (P/B) ratio of Prothena Corporation plc (PRTA) is 1.27
The dividend yield of Prothena Corporation plc (PRTA) is 0.00%
The market capitalization of Prothena Corporation plc (PRTA) is $755.47M
The stock symbol (or ticker) of Prothena Corporation plc is PRTA